{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T01:07:26Z","timestamp":1786237646303,"version":"build-2736575974"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008021","name":"Bristol Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008021","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study describes economic burden of obstructive hypertrophic cardiomyopathy (HCM) in France, with consideration of disease severity as measured by New York Heart Association (NYHA) class.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This observational, retrospective study used data from the French National Health Data System. Adults (\u226518) with at least one disease related hospitalization during 2012\u201318 were included. Patients with &amp;lt;1-year follow-up or phenocopy disorders were excluded. Patients were stratified by disease severity class based on disease specific treatments and symptoms. Healthcare resources use, and costs were estimated per patient-year (PY). Annual cost before and after septal reduction therapies (SRT) was estimated. Overall, 6823 patients were identified (baseline NYHA class I\u2013IV: 4%, 32%, 60%, and 4%, respectively). Mean (standard deviation) follow-up was 4.4 (2.5) years, comprising 30 228 PYs. Total burden was \u20ac388 million (\u20ac12 824 per PY), and higher NYHA class was associated with higher cost per patient year: \u20ac8881 and \u20ac22 818 for classes I and IV, respectively. Hospitalizations accounted for most costs (54%); 71% were cardiovascular-related hospitalizations, 46% disease-related. Mean cost per PY was lower 1 year before vs. after SRT, including the intervention (\u20ac13 726 vs. \u20ac18 565). Mean sick-leave-related costs per PY were \u20ac310, \u20ac673, \u20ac757, and \u20ac774 for classes I\u2013IV, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Obstructive HCM has a high economic burden driven by cardiovascular hospitalizations. Higher disease severity yielded higher costs associated with medical care and sick leave than lower classes. Results support need for new therapies to improve both symptoms and disease severity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ehjqcco\/qcaf096","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T08:59:35Z","timestamp":1756976375000},"page":"189-197","source":"Crossref","is-referenced-by-count":1,"title":["A nationwide study of the economic burden of obstructive hypertrophic cardiomyopathy in France"],"prefix":"10.1093","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1782-1118","authenticated-orcid":false,"given":"Philippe","family":"Charron","sequence":"first","affiliation":[{"name":"AP-HP, IHU-ICAN, INSERM 1166, Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9-Salp\u00eatri\u00e8re , 47 boulevard de l\u2019h\u00f4pital, Paris 75013 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Zema","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Princeton, NJ 08648"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois-Emery","family":"Cott\u00e9","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , HEOR, Rueil\u2013Malmaison 92500 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Juban","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , HEOR, Rueil\u2013Malmaison 92500 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aur\u00e9lie","family":"Schmidt","sequence":"additional","affiliation":[{"name":"Heva, Pharmaco-epidemiology , Lyon 69006 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taryn","family":"Krause","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Global HEOR Cardiovascular, Uxbridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Hurst","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb , Global HEOR Cardiovascular, Uxbridge ,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Heva, Pharmaco-epidemiology , Lyon 69006 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-No\u00ebl","family":"Trochu","sequence":"additional","affiliation":[{"name":"CNRS, INSERM, Institut du Thorax, Centre Hospitalo-Universitaire Nantes, Nantes Universit\u00e9 , Nantes 44007 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"2026030502064603600_qcaf096-B1","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1093\/eurheartj\/ehm342","article-title":"Classification of the cardiomyopathies: a position statement from the European Society of Cardiology working group on myocardial and pericardial diseases","volume":"29","author":"Elliott","year":"2008","journal-title":"Eur Heart J"},{"key":"2026030502064603600_qcaf096-B2","first-page":"e558","article-title":"Aha\/acc guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy","volume":"2020","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"2026030502064603600_qcaf096-B3","first-page":"47","article-title":"Hypertrophic obstructive cardiomyopathy","volume":"116","author":"Batzner","year":"2019","journal-title":"Dtsch Arztebl Int"},{"key":"2026030502064603600_qcaf096-B4","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3390\/jcm9040920","article-title":"The public health burden of cardiomyopathies: insights from a nationwide inpatient study","volume":"9","author":"Lannou","year":"2020","journal-title":"J Clin Med"},{"key":"2026030502064603600_qcaf096-B5","doi-asserted-by":"crossref","first-page":"S118","DOI":"10.37765\/ajmc.2021.88629","article-title":"Hypertrophic cardiomyopathy considerations for the managed care pharmacist","volume":"27","author":"Taddei-Allen","year":"2021","journal-title":"Am J Manag Care"},{"key":"2026030502064603600_qcaf096-B6","first-page":"2733","article-title":"ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC)","volume":"2014","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"2026030502064603600_qcaf096-B7","doi-asserted-by":"crossref","first-page":"e0191214","DOI":"10.1371\/journal.pone.0191214","article-title":"Identifying unmet clinical need in hypertrophic cardiomyopathy using national electronic health records","volume":"13","author":"Pujades-Rodriguez","year":"2018","journal-title":"PLoS One"},{"key":"2026030502064603600_qcaf096-B8","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/joa3.12215","article-title":"Burden and trends of arrhythmias in hypertrophic cardiomyopathy and its impact of mortality and resource utilization","volume":"35","author":"Tripathi","year":"2019","journal-title":"J Arrhythm"},{"key":"2026030502064603600_qcaf096-B9","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(16)31321-6","article-title":"Hypertrophic obstructive cardiomyopathy","volume":"389","author":"Veselka","year":"2017","journal-title":"Lancet"},{"key":"2026030502064603600_qcaf096-B10","doi-asserted-by":"crossref","first-page":"S151","DOI":"10.1016\/j.jval.2022.09.730","article-title":"Ee487 quantifying the economic burden of obstructive hypertrophic cardiomyopathy (hcm) in the UK","volume":"25","author":"Hurst","year":"2022","journal-title":"Value Health"},{"key":"2026030502064603600_qcaf096-B11","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.ijcard.2012.01.099","article-title":"Economic burden of patients with various etiologies of chronic systolic heart failure analyzed by resource use and costs","volume":"156","author":"Biermann","year":"2012","journal-title":"Int J Cardiol"},{"key":"2026030502064603600_qcaf096-B12","doi-asserted-by":"crossref","first-page":"E866","DOI":"10.25270\/jic\/22.00150","article-title":"Costs and healthcare resource utilization for obstructive hypertrophic cardiomyopathy with septal reduction therapy","volume":"34","author":"Butzner","year":"2022","journal-title":"J Invasive Cardiol"},{"key":"2026030502064603600_qcaf096-B13","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.amjcard.2022.12.030","article-title":"Clinical outcomes, resource utilization, and treatment over the disease course of symptomatic obstructive hypertrophic cardiomyopathy in the United States","volume":"192","author":"Desai","year":"2023","journal-title":"Am J Cardiol"},{"key":"2026030502064603600_qcaf096-B14","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1080\/13696998.2021.1978242","article-title":"Clinical and economic burden of obstructive hypertrophic cardiomyopathy in the United States","volume":"24","author":"Jain","year":"2021","journal-title":"J Med Econ"},{"key":"2026030502064603600_qcaf096-B15","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s40119-022-00257-7","article-title":"Treatment changes, healthcare resource utilization, and costs among patients with symptomatic obstructive hypertrophic cardiomyopathy: a claims database study","volume":"11","author":"Owens","year":"2022","journal-title":"Cardiol Ther"},{"key":"2026030502064603600_qcaf096-B16","doi-asserted-by":"crossref","first-page":"27","DOI":"10.15511\/ejcm.16.00231","article-title":"Hypertrophic obstructive cardiomyopathy and the cost of treatment","volume":"4","author":"Jan","year":"2016","journal-title":"EJCM"},{"key":"2026030502064603600_qcaf096-B17","first-page":"E8-E13","article-title":"Differences in short-term outcomes and hospital-based resource utilization between septal reduction strategies for hypertrophic obstructive cardiomyopathy","volume":"34","author":"Yandrapalli","year":"2022","journal-title":"J Invasive Cardiol"},{"key":"2026030502064603600_qcaf096-B18","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.respe.2017.05.004","article-title":"Value of a national administrative database to guide public decisions: from the syst\u00e8me national d\u2019information interr\u00e9gimes de l\u2019assurance maladie (sniiram) to the syst\u00e8me national des donn\u00e9es de sant\u00e9 (snds) in France","volume":"65","author":"Tuppin","year":"2017","journal-title":"Rev Epidemiol Sante Publique"},{"key":"2026030502064603600_qcaf096-B19","article-title":"Clinical burden of obstructive hypertrophic cardiomyopathy in France","author":"Charron","year":"2025","journal-title":"Frontiers (Boulder)"},{"key":"2026030502064603600_qcaf096-B20","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/MLR.0000000000000471","article-title":"The best use of the Charlson comorbidity index with electronic health care database to predict mortality","volume":"54","author":"Bannay","year":"2016","journal-title":"Med Care"},{"key":"2026030502064603600_qcaf096-B21","author":"S\u00e9curit\u00e9 sociale"},{"key":"2026030502064603600_qcaf096-B22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","article-title":"The strengthening the reporting of observational studies in epidemiology (strobe) statement: guidelines for reporting observational studies","volume":"61","author":"von Elm","year":"2008","journal-title":"J Clin Epidemiol"},{"key":"2026030502064603600_qcaf096-B23","article-title":"Clinical and economic burden of hypertrophic obstructive cardiomyopathy in Germany","author":"Sedaghat-Hamedani","year":"2022","journal-title":"Dtsch Ges Kardiologie (DGK) Herztage 2022"},{"key":"2026030502064603600_qcaf096-B24","doi-asserted-by":"crossref","first-page":"S50","DOI":"10.1016\/j.jval.2023.09.274","article-title":"Characterizing the economic burden associated with obstructive HCM: health care resource use and costs in England.","volume":"26","author":"Osman","year":"2023","journal-title":"Value in health"},{"key":"2026030502064603600_qcaf096-B25","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1093\/eurheartj\/ehad194","article-title":"2023 ESC guidelines for the management of cardiomyopathies","volume":"44","author":"Arbelo","year":"2023","journal-title":"Eur Heart J"},{"key":"2026030502064603600_qcaf096-B26","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.jtcvs.2015.07.063","article-title":"Symptom assessment and exercise impairment in surgical decision making in hypertrophic obstructive cardiomyopathy: relationship to outcomes","volume":"150","author":"Desai","year":"2015","journal-title":"J Thorac Cardiovasc Surg"},{"key":"2026030502064603600_qcaf096-B27","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1093\/eurheartj\/ehl041","article-title":"Left ventricular outflow tract obstruction and sudden death risk in patients with hypertrophic cardiomyopathy","volume":"27","author":"Elliott","year":"2006","journal-title":"Eur Heart J"},{"key":"2026030502064603600_qcaf096-B28","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1016\/j.cardfail.2022.03.101","article-title":"New York Heart Association functional class and mortality in obstructive hypertrophic cardiomyopathy","volume":"28","author":"Lakdawala","year":"2022","journal-title":"J Card Fail"}],"container-title":["European Heart Journal - Quality of Care and Clinical Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjqcco\/advance-article-pdf\/doi\/10.1093\/ehjqcco\/qcaf096\/64204972\/qcaf096.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/2\/189\/64204972\/qcaf096.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article-pdf\/12\/2\/189\/64204972\/qcaf096.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T07:07:01Z","timestamp":1772694421000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjqcco\/article\/12\/2\/189\/8247766"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,4]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2025,9,4]]},"published-print":{"date-parts":[[2026,3,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjqcco\/qcaf096","relation":{},"ISSN":["2058-5225","2058-1742"],"issn-type":[{"value":"2058-5225","type":"print"},{"value":"2058-1742","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2025,9,4]]}}}